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doi:10.1016/j.jtcvs.2004.02.019Objective: In an effort to minimize transfusions in patients undergoing elective
coronary artery bypass grafting operations after recent clopidogrel exposure, we
studied laboratory tests predictive of platelet dysfunction and used a strict algo-
rithm-driven treatment of bleeding.
Methods: Forty-five patients receiving clopidogrel within 6 days of the operation
and 45 control subjects were studied. Prothrombin time, activated partial thrombo-
plastin time, platelet count, and platelet function test results were measured before
heparinization, after protamine administration, and then every 2 hours. No transfu-
sions were administered unless a patient met both laboratory and clinical criteria.
Results: Algorithm-driven treatment of bleeding significantly reduced the mean
units of all blood components transfused by about one third, as shown by compar-
ison with current control and historical data. Compared with current control sub-
jects, clopidogrel recipients required significantly more transfusions of platelets (9.0
 1.7 vs 1.2  0.5 U; P  .0001) and packed red blood cells (4.3  0.6 vs 2.3 
0.5 U; P  .01) and required longer periods of controlled ventilation (12.4  1.3 vs
8.6  0.8 hours; P  .02). Preoperative platelet dysfunction before heparin
administration for cardiopulmonary bypass, as measured by using adenosine diphos-
phate aggregometry (response 40%), predicted all but 1 case of severe coagu-
lopathy requiring multiple transfusions (16.6  2.8 U of platelets and 5.8  1.0 U
of packed red blood cells).
Conclusions: A strict transfusion algorithm can reduce the transfusion requirement
for all blood components. Preheparin testing of platelet function with adenosine
diphosphate aggregometry can identify patients at highest risk for perioperative
bleeding and transfusions and might further reduce the perioperative transfusion
requirement.
Clopidogrel is frequently administered to patients undergoing coro-nary angiography in anticipation of percutaneous coronary inter-vention.1,2 If angiography indicates coronary artery bypass grafting(CABG) rather than percutaneous coronary intervention, the ques-tion arises of whether to delay operation in all but urgent cases.3 Inaddition, many patients are now receiving long-term clopidogrel
with or without aspirin for secondary prevention of coronary or cerebrovascular
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CDischemic events,4-6 and some will require CABG or other
operations urgently. The effect of clopidogrel on platelets is
irreversible,7 and when discontinued, full recovery of plate-
let function takes 3 to 5 days.8,9 Some have recommended
that clopidogrel be stopped 5 days before the elective op-
eration,10,11 and others have recommended stopping the
drug at 7 days.12 Optimal management of these patients
remains uncertain.
In the Clopidogrel in Unstable Angina to Prevent Recur-
rent Events (CURE) trial, the relative risk of major bleeding
increased by 50% for patients who received clopidogrel
within 5 days of the operation.10-15 In 3 single-center ob-
servational studies, patients who received clopidogrel
within 7 days of surgical intervention, with or without
concomitant aspirin, required significantly more periopera-
tive blood component transfusions.2,16,17 Hongo and col-
leagues2 studied 224 consecutive patients, finding that the
59 patients with preoperative clopidogrel exposure received
significantly more units of packed red blood cells (PRBCs),
platelets, and fresh frozen plasma (FFP) and had signifi-
cantly more chest tube drainage than patients without pre-
operative clopidogrel exposure. Similar findings were re-
ported by Yende and Wunderlink16 and by Ray and
coworkers.17 In these studies administration of blood com-
ponents was not based on any prespecified laboratory or
clinical criteria.
A chart review in our institution revealed a high inci-
dence and volume of PRBC, platelet, and FFP transfusion in
patients receiving clopidogrel within 6 days of CABG sur-
gery. In view of the increased morbidity and mortality
associated with transfusion in patients undergoing
CABG,18-26 we prospectively studied patients undergoing
elective primary CABG with and without clopidogrel to
identify means of reducing excess transfusions through use
of a strict transfusion algorithm. This algorithm was guided
by clinical criteria and by serial measurement of coagulation
and tests of platelet function, which would potentially yield
predictive information about the development of significant
coagulopathy.
Methods
The study design and protocol were approved by the Institutional
Review Board at St Luke’s Episcopal Hospital. After informed
consent was obtained and in accord with institutional guidelines,
we prospectively enrolled 90 patients undergoing primary elective
CABG surgery with cardiopulmonary bypass (CPB). This popu-
lation included 45 patients who received clopidogrel by mouth
within 6 days of surgical intervention (clopidogrel group) and 45
patients who had never received clopidogrel (control group). After
enrollment of each clopidogrel-exposed patient, we enrolled the
next available consenting patient on the surgical schedule who had
never received clopidogrel. Patients who had recently received any
platelet inhibitor other than aspirin or any other anticoagulant were
excluded, as were patients with any preexisting bleeding disorders,
end-stage renal disease, or end-stage heart failure.
426 The Journal of Thoracic and Cardiovascular Surgery ● SeptCPB was performed by using a standard circuit and crystalloid
prime. Anticoagulation was achieved with heparin (300 U/kg).
Aprotinin was not used in any patient; aminocaproic acid was used
according to the preference of the anesthesiologist in 42% of
patients receiving clopidogrel and 31% of control subjects. The
degree of hypothermia induced during CPB was monitored by
using a nasopharyngeal temperature probe and ranged from 28°C
to 32°C. Patients were rewarmed to a target temperature of 36.5°C
before CPB was discontinued. After weaning from CPB, heparin
was neutralized with protamine sulfate (1.0-1.5 mg/100 U hepa-
rin). When patients achieved hemodynamic stability, weaning
from mechanical ventilation was accomplished according to an
institutional protocol, with incremental decreases in intermittent
mandatory ventilation rates from 10 to 4 beats/min and then to zero
(with 5 cm H2O of continuous positive airway pressure). Patients
were then tracheally extubated if the appropriate criteria (ie, neg-
ative inspiratory force of 25 cm H2O and vital capacity of at
least 12-15 mL/kg) were met.
Blood samples were collected from patients after anesthesia
induction but before heparinization for CPB, 15 minutes after
protamine administration, and then every 2 hours up to 8 hours.
Additional coagulation testing was done within 30 minutes after
completion of any platelet transfusion to assess the transfusion
effect. All samples were analyzed for hemoglobin level and coag-
ulation profile in an onsite rapid-response laboratory immediately
after collection. The coagulation profile included prothrombin
time, activated partial thromboplastin time, platelet count, and
platelet function, as determined by using 3 methods. These meth-
ods were adenosine diphosphate (ADP) aggregometry (Biodata,
Philadelphia, Pa), which requires 30 to 45 minutes, and 2 rapid-
response tests, Platelet Function Analyzer 100 (PFA-100; Dade
Behring, Miami, Fla) and Platelet Works (Helena Laboratories,
Beaumont, Tex), which require approximately 10 minutes each.
For ADP aggregometry, we measured the platelet aggregation
response of platelet-rich plasma (prepared by standard methods) to
a 2 mol/L concentration of ADP. Platelet function in this assay is
expressed as the percentage of light transmittance through a stan-
dardized glass tube containing the patient’s platelet-rich plasma. A
value of 70% to 100% indicated normal function, 50% to 69%
indicated mild dysfunction, 40% to 49% indicated moderate dys-
function, and 0% to 39% indicated severe dysfunction. A value of
less than 50% was selected a priori as the laboratory criterion for
platelet transfusion in our algorithm. For PFA-100 analysis, plate-
let function is expressed as the time to thrombotic occlusion
(closure) of an aperture in a membrane coated with collagen and
ADP. A closure time of 128 seconds or less indicated normal
platelet function. In the algorithm, a closure time of greater than
128 seconds was selected a priori as the laboratory criterion for
platelet transfusion. All normal ranges were determined in our
laboratory through study of healthy control subjects. The Platelet
Works, a newer rapid-response test, assesses platelet reactivity by
measuring the ratio of activated platelet count to nonactivated
platelet count in tubes containing ADP. Normal ranges had not
been determined in our laboratory for this test, and therefore
Platelet Works data were not used in any clinical decision making
and are not included.
No platelet or FFP units were administered after protamine
administration or in the postoperative period unless a patient met
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such cases, the laboratory results for the preheparin blood sample
were not considered. For the postprotamine blood sample, only the
PFA-100 analysis was available in the onsite rapid-response lab-
oratory; therefore, this value guided algorithm use. After admis-
sion to the intensive care unit (ICU), the primary assay for decision
making was ADP aggregometry. The clinical criterion for platelet
and FFP transfusion in the operating room was excessive micro-
vascular bleeding, as determined by the surgeon. In the ICU, the
clinical criterion was chest tube drainage of greater than 250 mL/h
after the first hour. If both laboratory and clinical criteria were met,
transfusion of platelets, FFP, or both proceeded with strict adher-
ence to the algorithm (Figure 1). After transfusion, blood tests
were repeated, and the algorithm was used until bleeding ceased.
During CPB, 1 U of PRBCs was administered only when the
hemoglobin level decreased to less than 6.0 g/dL. At all other
times, 1 U of PRBCs was transfused only if the hemoglobin level
decreased to less than 8.0 g/dL, except in patients with major
ongoing hemorrhage.
To estimate the algorithm’s efficacy, current data were com-
pared with historical data obtained in the chart review performed
during the 4-month period from September 1, 1999, through De-
cember 31, 1999, just before development and implementation of
the algorithm. Of all patients undergoing primary elective CABG
during that historical period, 53 received clopidogrel within 6 days
of surgical intervention, and 428 received none. Mean units of
PRBCs, platelets, and FFP administered in these 2 groups were
compared.
Statistical analysis was performed with SAS software (SAS
Institute, Inc, Cary, NC). A 2-tailed unpaired Student t test was
used to compare the mean values of the 2 independent groups, and
a 2 or Fisher exact test was used to compare categorical data.
Figure 1. Bleeding management algorithm used for tr
function; ADP, adenosine diphosphate; CT, closure tim
FFP, fresh frozen plasma.Values were reported as the mean  SE.
The Journal of ThoraciResults
The clopidogrel and control groups were demographically
TABLE 1. Demographic and clinical characteristics of the
study population
Characteristic
Clopidogrel
group
(n  45)
Control
group
(n  45) P value
Age, y 58 1.3 58 1.5 .86
Body weight, kg 85 2.5 90 2.5 .18
Male/female sex, n 31/14 35/10 .34
Preheparin aspirin exposure, % 29 (64) 22 (49) .14
Preheparin platelet count, 109/L 216 10 231 9 .24
Preheparin platelet function by
ADP aggregometry, %
51 4 78 2 .0001
Postprotamine platelet function by
ADP aggregometry, %
42 3 67 3 .0001
Preheparin platelet function by
PFA-100 analysis, s
112 12 96 6 .26
Postprotamine platelet function by
PFA-100 analysis, s
127 15 104 8 .13
Preheparin PT, s 13.4 0.9 12.2 0.1 .20
Preheparin aPTT 30.6 2.9 29.2 1.1 .66
Preoperative Hgb, g/dL 12.4 0.24 12.4 0.19 .93
Aminocaproic acid administration, % 19 (42) 14 (31) .27
Duration of CPB, min 73 6.2 63 3.6 .17
Mean no. of vessels bypassed 3.0 0.2 3.3 0.1 .20
ADP, Adenosine diphosphate; PFA, platelet function analyzer; PT, pro-
thrombin time; aPTT, activated partial thromboplastin time; Hgb, hemoglo-
bin; CPB, cardiopulmonary bypass.
ent of excessive microvascular bleeding. PF, Platelet
T, prothrombin time; PTT, partial thromboplastin time;eatm
e; Psimilar, including exposure to aspirin (Table 1). Platelet
c and Cardiovascular Surgery ● Volume 128, Number 3 427
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by means of ADP aggregometry but not by means of PFA-
100 analysis in both the preheparin and postprotamine blood
samples (Table 1). As expected, transfusions of both plate-
lets and PRBCs, but not FFP, were significantly greater in
the clopidogrel group (Table 2). Fifty-three percent of pa-
tients exposed to clopidogrel received platelet transfusions
compared with 13% of control subjects (P  .0001). FFP
was transfused with similar frequency (22% and 13%; P 
.27).
In the prospective control group, as compared with the
historical control group (Table 2), use of the algorithm
significantly reduced transfusions of platelets and FFP, but
not of PRBCs. The algorithm significantly reduced the use
of PRBCs in the prospective clopidogrel group compared
with that in the historical clopidogrel group.
Patients were stratified within the clopidogrel group by
degree of platelet dysfunction, as determined by means of
preheparin ADP aggregometry, to determine the sensitivity
of ADP aggregometry as a predictor of postoperative bleed-
ing (Table 3). Within the clopidogrel group, 2 of 4 patients
who underwent mediastinal reexploration for persistent
postoperative bleeding had identifiable surgical bleeding
points, which were ligated. The aggregometry data of these
2 patients were excluded from this analysis. Of the remain-
ing 43 clopidogrel-exposed patients, 12 had severe preop-
erative platelet dysfunction (40% light transmittance;
mean, 23.8%  2.8%), and 11 (92%) of these 12 received
platelet transfusions (mean, 16.6  2.8 U), as well as
multiple transfusions of PRBCs (mean, 5.8  1.0 U; Table
3). All 11 patients received intraoperative platelet transfu-
sions after protamine, and 6 of these required additional
platelet transfusions in the 4 hours after ICU admission. The
postprotamine platelet function of the 12th patient was
normal, raising the question of laboratory error in the pre-
heparin sample. Patients in the clopidogrel group with in-
termediate preoperative platelet dysfunction (40%–60%
TABLE 2. Component transfusion in prospective and retro-
spective patients undergoing CABG
Prospective Retrospective (historical)
Clopidogrel
group
(n  45)
Control group
(n  45)
Clopidogrel
group
(n  53)
Control group
(n  428)
PLT, U 9.0 1.7* 1.2 0.5 12.5 2.1* 2.3 0.3‡
PRBC, U 4.3 0.6* 2.3 0.5 6.4 0.8*,† 2.3 0.1
FFP, U 1.0 0.6 0.5 0.3 2.9 1.0* 1.0 0.1‡
PLT, Platelets; PRBC, packed red blood cells; FFP, fresh frozen plasma.
*P  .05 compared with control subjects enrolled in the same time period.
†P  .05 compared with prospective clopidogrel-exposed subjects.
‡P  .05 compared with prospective control subjects.light transmittance; mean, 50.8%  1.2%) had a signifi-
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(P  .001) and received significantly fewer platelet and
PRBC units (P  .05; Table 3). Patients with near-normal
or normal preoperative platelet function (60% light trans-
mittance; mean, 77.9%  2.4%) also received significantly
fewer units of platelets and PRBCs than did those with
severe dysfunction (P  .05). Similar results were obtained
by using the postprotamine results of ADP aggregometry
testing (Table 3). By contrast, PFA-100 analysis in both the
preheparin and postprotamine periods was not as predictive
of who would bleed and require platelet or PRBC transfu-
sions (Table 4). The Platelet Works data were similar to the
PFA-100 data in this regard and were not included.
The number of days elapsed since the last dose of clo-
pidogrel was not useful in estimating the degree of platelet
dysfunction (Tables 3 and 4). There were no differences
between groups stratified by degree of platelet dysfunction
in either mean or range of days elapsed since last exposure
to clopidogrel, up to and including 6 days. In the control
group, after exclusion of 1 patient who had an identifiable
surgical bleeding point on mediastinal reexploration, only 1
patient had severe preoperative platelet dysfunction, as
measured by means of ADP aggregometry (40% light
transmittance). However, this patient received no transfu-
sions because there was no evidence of clinical microvas-
cular bleeding. Only 3 (6.8%) of 44 control subjects re-
quired platelet transfusions, all given in the operating room,
when they met the appropriate clinical and laboratory cri-
teria of the algorithm. Only one of these patients had re-
ceived preoperative aspirin.
Total chest tube drainage was significantly greater in the
clopidogrel group (Table 5). Also, the duration of controlled
ventilation was significantly longer and there was a nonsig-
nificant trend toward longer postoperative hospitalization in
the clopidogrel group (Table 2). One patient, a clopidogrel
recipient who experienced a postoperative myocardial in-
farction and then adult respiratory distress syndrome, died
on postoperative day 5.
Discussion
The major objective of this study was to improve transfu-
sion management of patients undergoing CABG with a
recent history of clopidogrel treatment. Our data and those
of others clearly document the excess transfusion require-
ments of these patients.2,16,17 Two findings offer promise of
improved care: the use of a strict transfusion algorithm27,28
and the availability of a better predictor of patients who will
have severe bleeding. Use of the algorithm reduced the
mean units of all blood components transfused per patient
by about one third in both the prospective control and
clopidogrel groups compared with values in historical sub-
jects (Table 2). We attribute this to the strict limitation on
platelet transfusion, as well as to the nonspecific effect of
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exposed patients received 3.5 times more blood components
than did control subjects. A more effective treatment regi-
men is required for clopidogrel-exposed patients.
We anticipated that degree of bleeding would correlate
inversely with the number of days since the last clopidogrel
exposure. This was not the case. Instead, we found that
markedly abnormal ADP aggregometry (40% light trans-
mittance) in the pre-CPB period accurately identified 11 of
the 12 patients who received multiple transfusions (on av-
erage 17 U of platelets and 6 U of PRBCs). A regimen
providing earlier and more vigorous treatment of this group
of patients might have a significant effect on this difficult
clinical problem.
The obvious solution to the problem is to withhold
clopidogrel preoperatively until normal coagulation is re-
stored. The risks of acutely withdrawing this antiaggrega-
tory agent in patients undergoing elective CABG surgery
are probably minimal. However, patients requiring urgent or
emergency CABG present a dilemma. Should operation be
delayed while clopidogrel is withdrawn at the unknown risk
TABLE 3. ADP aggregometry and perioperative bleeding
ADP aggregometry,
% light
transmittance
No. of patients
(no. with aspirin exposure)
Last clopidog
exposure, d
Preheparin
40% 12 (9) 2.0 0.4
40%-60% 17 (11) 2.5 0.5
60% 14 (7) 2.3 0.4
Postprotamine
40% 18 (11) 2.0 0.4
40%-60% 18 (11) 2.1 0.4
60% 7 (5) 3.4 0.5
There were no significant differences between groups in the percentage
ADP, Adenosine diphosphate; PLT, platelet; PRBC, packed red blood cells
*P  .05 compared with 40%-60% and 60% light transmittance through
TABLE 4. PFA-100 analysis and perioperative bleeding
Closure
time, s
No. of patients
(no. with aspirin exposure)
Last clopidogrel
exposure, d
Preheparin
170 5 (3) 2.0 0.8
128-170 2 (2) 3.5 2.5
128 36 (23) 2.3 0.3
Postprotamine
170 6 (5) 1.8 0.3
128-170 4 (2) 2.0 1.0
128 33 (20) 2.4 0.3
There were no significant differences between groups in the percentage
clopidogrel-exposed subjects as classified by closure time.
PFA, Platelet function analyzer; PLT, platelet; PRBC, packed red blood ceof a thrombotic episode? Or should operation proceed with
The Journal of Thoracithe knowledge that excessive bleeding and increased trans-
fusions are likely?
Surgeons are justifiably wary of putting patients at risk of
TABLE 5. Postoperative characteristics of the study popu-
lation
Characteristic
Clopidogrel
group
(n  45)
Control
group
(n  45)
P
value
Total chest tube drainage in
24 h, mL
1329 154 965 73 .04
Mediastinal reexploration, n 4/45 1/45 .17
Duration of controlled
ventilation, h
16.9 1.5 12.8 0.9 .02
Duration of controlled
ventilation (excluding 5
patients requiring
mediastinal reexploration), h
12.4 1.3 8.6 0.8 .02
Duration of hospitalization, d 8.3 1.1 6.6 0.3 .11
Mortality, n 1 0 1.0
Range, d
PLT transfusion
PRBC
transfusion, UIncidence, % Units
1-5 92* 16.6 2.8* 5.8 1.0*
1-6 35 3.4 1.2 2.2 0.5
1-5 21 1.7 1.0 1.7 0.4
1-6 83* 11.6 1.9* 5.1 0.7*
1-6 22 3.7 2.1 1.4 0.4
1-5 14 0.9 0.9 1.9 0.6
tients receiving aspirin.
ardized glass tubes, indicating platelet aggregation response.
Range, d
PLT transfusion PRBC
transfusion, UIncidence, % Units
1-5 40 9.6 7.0 4.6 1.5
1-6 50 2.0 2.0 5.5 4.5
1-6 46 6.3 1.3 2.7 0.4
1-3 67 12.0 4.6 3.3 1.5
1-5 25 3.0 3.0 1.5 0.5
1-6 44 5.9 1.5 3.2 0.5
atients receiving aspirin. There were no significant differences betweenrel
of pa
.
standof ppreventable perioperative bleeding, mediastinal tamponade,
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surgical reexploration for bleeding.3 Blood transfusions dur-
ing cardiac surgery are associated with increased in-hospital
morbidity (infectious complications,20,21,22 sepsis,23 and re-
nal dysfunction24) and mortality.23,26
Since publication of the CAPRIE trial29 and the
CLASSICS study,30 chronic clopidogrel administration in
patients with atherosclerotic disease, prior coronary stent-
ing, or both has become common. Furthermore, the results
of the CURE trial argue strongly for adding clopidogrel to
aspirin as soon as possible after hospital admission for
management of unstable angina and myocardial infarction
without ST-segment elevation,10,13 despite the increased
risk of major nonsurgical bleeding14,15 that was described as
“life-threatening in nearly half of the cases.”10,15 In the trial,
clopidogrel was discontinued in most patients scheduled for
CABG surgery (the median time was 5 days before surgical
intervention),10 which might be an impractical goal in most
US centers. For those patients who did undergo CABG
surgery less than 5 days after clopidogrel was discontinued,
the relative risk of major or life-threatening bleeding in-
creased by 50%.10,13-15
An alternative suggested by others would be to withhold
clopidogrel before diagnostic angiography in patients at
increased risk of requiring CABG surgery until the timing
of the operation is determined.14 In its guidelines for man-
aging patients with unstable angina and myocardial infarc-
tion without ST-segment elevation, the American College
of Cardiology/American Heart Association Task Force on
Practice Guidelines notes that clopidogrel is withheld in
many centers in which patients with acute coronary syn-
dromes undergo diagnostic catheterization within 24 to 36
hours of admission until it is clear that CABG surgery will
not be scheduled within the next several days.13 These
guidelines suggest 2 options: first, if immediate percutane-
ous transluminal coronary angioplasty is indicated, then a
loading dose of clopidogrel can be given in the cardiac
catheterization laboratory; second, if immediate percutane-
ous transluminal coronary angioplasty is not indicated and
so delayed, then clopidogrel can be started after catheter-
ization.13 If clopidogrel has been administered and the de-
cision to delay surgery is made, preoperative ADP aggre-
gometry would be helpful in reevaluating the risk of
bleeding and transfusion requirements before any operation
is undertaken. When surgical intervention cannot be safely
delayed, patients may receive platelets to achieve a target
ADP aggregation response of greater than 40% if bleeding
develops after protamine administration. In our study a total
of approximately 17 U of platelets was required to correct
microvascular bleeding in similar patients.
Our study had several limitations. First, although the
clopidogrel and control groups were demographically sim-
ilar, they were not randomized to clopidogrel exposure.
430 The Journal of Thoracic and Cardiovascular Surgery ● SeptTherefore, confounding factors, such as preoperative aspirin
exposure, may have influenced outcome.
Second, neither of the rapid-response platelet aggrega-
tion tests was useful in predicting who would bleed. ADP
aggregometry requires that blood be separated to obtain
platelet-rich plasma, a technique not available in a rapid-
response laboratory. In our study, ADP aggregometry re-
quired at least 30 minutes to complete and did not allow
prompt treatment of bleeding.
Third, surgeons caring for the patients in our study were
not blinded to preoperative exposures to antiplatelet medi-
cations. This knowledge may have biased their decision on
microvascular bleeding. This limitation was mitigated in
part by strict adherence to the bleeding management algo-
rithm.
Finally, bleeding may have been somewhat dependent on
individual surgical technique and skill, a potential con-
founder that this study was not powered to detect.
Despite these limitations, this prospective study demon-
strates the predictability of perioperative bleeding and its
consequences in patients undergoing elective CABG sur-
gery after recent clopidogrel exposure. Serious consider-
ation should be given to discontinuing clopidogrel earlier
than 5 days before an elective operation. Preoperative or
pre-CPB testing of platelet function by means of ADP
aggregometry can identify patients at highest risk for bleed-
ing and facilitate the decision to delay or proceed with the
operation. When surgical intervention cannot be safely de-
layed, transfusion of platelets to achieve a target ADP
aggregation response of at least 40% and possibly higher
would seem reasonable, although its effectiveness requires
demonstration. A more rapid method for assessing platelet
ADP receptor function in a rapid-response laboratory would
allow earlier transfusion decisions for clopidogrel-exposed
patients. Additional study will be necessary to determine
how early clopidogrel may be stopped before surgical in-
tervention to allow recovery of platelet function, to deter-
mine the risks of acute clopidogrel withdrawal, and to
determine whether some other algorithm for preoperative or
intraoperative platelet transfusions will decrease overall
transfusion.
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